慢性乙型肝炎外周血T淋巴细胞亚群变化的Meta分析

易婉婉; 孙奋勇; 易婉婉; 孙奋勇

doi:10.13898/j.cnki.issn.1000-2200.2016.04.005

[1]

VAN CAMPENHOUT MJ,JANSSEN HL.How to achieve immune control in chronic hepatitis B?[J].Hepatol Int,2015,9(1):9.

[2]

LIM SG,AMARAPURKAR DN,CHAN HL,et al.Reimbursement policies in the Asia-Pacific for chronic hepatitis B[J].Hepatol Int,2015,9(1):43.

[3]

PERZ JF,ARMSTRONG GL,FARRINGTON LA,et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol,2006,45(4):529.

[4]

LIU Y,HUANG R,XIONG Y,et al.Soluble CD40 ligand-activated B cells from patients with chronic hepatitis B virus infection as antigen presenting cells to induce hepatitis B virus specific cytotoxic T lymphocytes[J].Biochem Biophys Res Commun,2014,450(1):61.

[5]

DIAO H,HE J,ZHENG Q,et al.A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment[J].Immunol Lett,2014,160(1):65.

[6]

YAN Z,ZHOU J,ZHANG M,et al.Telbivudine decreases proportion of peripheral blood CD4⁺CD25⁺CD127low T cells in parallel with inhibiting hepatitis B virus DNA[J].Mol Med Report,2014,9(5):2024.

[7]

中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南2010年更新版[J/CD].中华实验和临床感染病杂志(电子版),2011,5(1):79.

[8]

冯广贵.慢性乙型肝炎病毒感染者外周血T细胞亚群变化分析[J].检验医学与临床,2010,7(1):21.

[9]

何英,张允奇,吴润香,等.慢性乙型肝炎患者外周血T淋巴细胞亚群变化与病毒复制的关系[J].检验医学,2009,24(11):808.

[10]

江浪进,陈欣.慢性乙型肝炎患者外周血T淋巴细胞亚群变化临床研究[J].中国实验诊断学,2013,17(7):1235.

[11]

刘曦东.HBV相关疾病患者血清IL-6、T淋巴细胞亚群、HBV DNA的变化及临床意义[J].山东医药,2011,51(33):47.

[12]

欧强,陈良,孙洪清,等.慢性HBV感染者外周血T淋巴细胞亚群和NK细胞活性变化[J].临床肝胆病杂志,2006,22(4):277.

[13]

邱清芳.乙肝相关疾病患者细胞免疫功能与HBV-DNA含量相关性研究[J].中国实验诊断学,2009,13(9):1260.

[14]

唐星火,卢东红.乙型肝炎相关疾病HBV-DNA载量与细胞免疫功能的研究[J].广西医科大学学报,2007,24(4):544.

[15]

滕惠琴,张盛杰,齐艳艳,等.慢性乙型肝炎病毒感染者T淋巴细胞亚群的变化[J].中国肝脏病学,2012,17(2):108.

[16]

吴昊,李钰.慢性乙型肝炎128例外周血T淋巴细胞亚群检测分析结果[J].中华内科学杂志,2006,1(1):26.

[17]

余晶,邱华,毛德文,等.病毒含量不同的慢性乙型肝炎患者T淋巴细胞亚群比较[J].广西中医学院学报,2009,12(1):1.

[18]

朱苏兰,鲁陈,熊德琴,等.慢性乙型肝炎病毒感染者外周血T细胞亚群分析及与病毒载量相关性研究[J].检验医学与临床,2013,10(9):1118.

[19]

JING Y,SRIPLUNG H,GEATER A,et al.Effect of viral load on T-lymphocyte failure in patients with chronic hepatitis B[J].World J Gastroenterol,2008,14(7):1112.

[20]

CAO W,QIU ZF,LI TS.Parallel decline of CD8⁺CD38⁺lymphocytes and viremia in treated hepatitis B patients[J].World J Gastroenterol,2011,17(17):2191.

[21]

杜振华,鲍布和,王仁杰,等.外周血DNT细胞和T细胞亚群检测在乙型肝炎病毒感染者诊断中的意义[J].实用肝脏病杂志,2014,17(6):579.

[22]

WU ZQ,TAN L,LIU T,et al.Evaluation of changes of serum hepatitis B surface antigen from a different perspective[J].World J Gastroenterol,2015,21(9):2739.

[23]

ZHOU Y,ZHANG H,LI Y.IL-35 expression in peripheral blood CD4⁺T cells from chronic hepatitis B virus-infected patients directly correlates with virus load[J].Cytokine,2015,73(1):169.

[24]

JO YJ,KIM KA,LEE JS,et al.Long-term virological outcome in chronic hepatitis B patients with a partial virological response to entecavir[J].Korean J Intern Med,2015,30(2):170.

[25]

PELLICELLI AM,VIGNALLY P,MESSINA V,et al.Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma[J].Ann Hepatol,2014,13(4):376.

[26]

CHO JY,PAIK YH,SOHN W,et al.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease[J].Gut,2014,63(12):1943.

[27]

HSU YC,WU CY,LAE HY,et al.Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B[J].J Antimicrob Chemother,2014,69(7):1920.

[28]

WAN R,LIU H,WANG X,et al.Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B[J].Int J Clin Exp Med,2015,8(1):961.